dc.creator | Azariadis K., Gatselis N.K., Koukoulis G.K., Dalekos G.N. | en |
dc.date.accessioned | 2023-01-31T07:34:56Z | |
dc.date.available | 2023-01-31T07:34:56Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1136/bcr-2018-228524 | |
dc.identifier.issn | 1757790X | |
dc.identifier.uri | http://hdl.handle.net/11615/71024 | |
dc.description.abstract | Glycogenic hepatopathy (GH) is a rare complication of poorly controlled type 1 diabetes mellitus (T1DM). We present a 19-year-old woman with T1DM and autoimmune thyroiditis who admitted to our department because of abrupt onset intermittent abdominal pain in the right upper quadrant accompanied by laboratory evidence of acute anicteric hepatitis. Physical examination revealed significant hepatomegaly but the common imagining studies were negative. Following exclusion of common causes of acute hepatitis and because of the presence of smooth muscle antibodies in a young female patient with already established two autoimmune diseases, a liver biopsy was performed in order to exclude the potential presence of autoimmune hepatitis. However, liver histology showed typical findings of GH. Intense treatment targeting strict glycemic control resulted in normalisation of liver biochemistry. This case underlines that GH should be considered as a rare cause of acute hepatitis in T1DM patients with poor glycemic control. © 2019 BMJ Publishing Group Limited. No commercial re-use. See rights and permissions. Published by BMJ. | en |
dc.language.iso | en | en |
dc.source | BMJ Case Reports | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063256106&doi=10.1136%2fbcr-2018-228524&partnerID=40&md5=f437819e6a2f221ed96b67043e9123fe | |
dc.subject | alanine aminotransferase | en |
dc.subject | alkaline phosphatase | en |
dc.subject | aspartate aminotransferase | en |
dc.subject | gamma glutamyltransferase | en |
dc.subject | glycosylated hemoglobin | en |
dc.subject | insulin glargine | en |
dc.subject | insulin glulisine | en |
dc.subject | levothyroxine | en |
dc.subject | liver enzyme | en |
dc.subject | antidiabetic agent | en |
dc.subject | glycogen | en |
dc.subject | insulin | en |
dc.subject | insulin glulisine | en |
dc.subject | abdominal pain | en |
dc.subject | adult | en |
dc.subject | anorexia | en |
dc.subject | Article | en |
dc.subject | body mass | en |
dc.subject | case report | en |
dc.subject | clinical article | en |
dc.subject | Cushingoid syndrome | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | glycemic control | en |
dc.subject | glycogenic hepatopathy | en |
dc.subject | Hashimoto disease | en |
dc.subject | hepatitis | en |
dc.subject | hepatomegaly | en |
dc.subject | human | en |
dc.subject | human tissue | en |
dc.subject | insulin dependent diabetes mellitus | en |
dc.subject | insulin treatment | en |
dc.subject | liver biopsy | en |
dc.subject | liver disease | en |
dc.subject | liver histology | en |
dc.subject | low carbohydrate diet | en |
dc.subject | physical examination | en |
dc.subject | priority journal | en |
dc.subject | satiety | en |
dc.subject | young adult | en |
dc.subject | analogs and derivatives | en |
dc.subject | complication | en |
dc.subject | insulin dependent diabetes mellitus | en |
dc.subject | liver function test | en |
dc.subject | metabolism | en |
dc.subject | subcutaneous drug administration | en |
dc.subject | Diabetes Mellitus, Type 1 | en |
dc.subject | Female | en |
dc.subject | Glycogen | en |
dc.subject | Hepatomegaly | en |
dc.subject | Humans | en |
dc.subject | Hypoglycemic Agents | en |
dc.subject | Infusions, Subcutaneous | en |
dc.subject | Insulin | en |
dc.subject | Liver Function Tests | en |
dc.subject | Young Adult | en |
dc.subject | BMJ Publishing Group | en |
dc.title | Glycogenic hepatopathy as a cause of severe deranged liver enzymes in a young patient with type 1 diabetes mellitus | en |
dc.type | journalArticle | en |